18FDG PET in oncology: The best and the worst (Review)

  • Authors:
    • Tarik Belhocine
    • Karoline Spaepen
    • Michelle Dusart
    • Catherine Castaigne
    • Kristof Muylle
    • Pierre Bourgeois
    • Daniel Bourgeois
    • Lawrence Dierickx
    • Patrick Flamen
  • View Affiliations

  • Published online on: May 1, 2006     https://doi.org/10.3892/ijo.28.5.1249
  • Pages: 1249-1261
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The clinical added-value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18FDG PET) in the management of oncology patients is increasingly documented. In the present review, we discuss both the benefits and the limitations of 18FDG PET in different cancers. Considering the literature data and our own experience, we also indicate the best clinical approach to optimize the use of metabolic imaging in oncology.

Related Articles

Journal Cover

May 2006
Volume 28 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Belhocine, T., Spaepen, K., Dusart, M., Castaigne, C., Muylle, K., Bourgeois, P. ... Flamen, P. (2006). 18FDG PET in oncology: The best and the worst (Review). International Journal of Oncology, 28, 1249-1261. https://doi.org/10.3892/ijo.28.5.1249
MLA
Belhocine, T., Spaepen, K., Dusart, M., Castaigne, C., Muylle, K., Bourgeois, P., Bourgeois, D., Dierickx, L., Flamen, P."18FDG PET in oncology: The best and the worst (Review)". International Journal of Oncology 28.5 (2006): 1249-1261.
Chicago
Belhocine, T., Spaepen, K., Dusart, M., Castaigne, C., Muylle, K., Bourgeois, P., Bourgeois, D., Dierickx, L., Flamen, P."18FDG PET in oncology: The best and the worst (Review)". International Journal of Oncology 28, no. 5 (2006): 1249-1261. https://doi.org/10.3892/ijo.28.5.1249